FDA warns Arizona firm over numerous alleged disease claims

By Hank Schultz contact

- Last updated on GMT

©Getty Images - Ildo Frazao
©Getty Images - Ildo Frazao

Related tags: regulations, Regulation, disease claims

An Arizona supplement marketer has been warned by FDA over claims relating to blood sugar management, stress relief, immunity and more.

The US Food and Drug Administration sent a warning letter to ICL Health, LLC, based in Tucson.  The company markets several supplements, all attributed to the company’s principal, Dr James L. Wilson, ND.

Among the products cited in the warning letter are Good Sugar, a blood sugar management product featuring minerals and herbs, Super Immune Space Sprinkles, an immunity product aimed at children, Super Immune Space Sprinkles, Cortisol Stress Reset, Nat-Stim and others.

The warning letter claims that the company was making claims to treat a host of conditions, including alcoholism, autoimmune diseases, fibromyalgia, depression and rheumatoid arthritis.

Specific claims

Among some of the many specific claims for ingredients and formulas cited by the Agency were these:

  • “Some researchers believe this [L-Lysine’s] ability to save off outbreaks also helps in the prevention of many other diseases related to cranial nerves such as migraines, Meniere’s disease, and Bell’s palsy.”
  • “[Ingredient(s) in Dr. Wilson’s Nat-Stim are] essential for immune function . . . . Stress and Immune Function . . . With chronic stress, this cortisol-related decrease in immune function can leave you more susceptible to colds, flu and other infections, and potentially make you more vulnerable to serious illness and degenerative disease down the road, as well as to the development of allergies and autoimmune disorders.”
  • “Can people with diabetes or metabolic syndrome take Dr. Wilson’s Good Sugar? . . . Diabetics and people with metabolic syndrome may find that Good Sugar . . . helps them feel their best.”

The warning letter resulted from a review of the company’s various websites, not a physical inspection.  FDA had given the company 15 days to respond from the issuance of the letter, which was dated Sept. 20, 2021.  The letter was posted on the FDA website on Oct. 5.

Related news

Show more

Related products

show more

Innovation in Postbiotics and Immunity Effects

Innovation in Postbiotics and Immunity Effects

Morinaga Milk Industry Co., Ltd. | 13-Jan-2023 | Technical / White Paper

With increased research that supports the link between human health and gut microbiome, postbiotics are an emerging supplement or ingredient that is beneficial...

Why you should add chews to your VMS portfolio

Why you should add chews to your VMS portfolio

Catalent | 10-Jan-2023 | Insight Guide

In the supplement market there are several factors that impact the consumer experience, a critical one being the delivery format. Supplement users are...

Related suppliers

Follow us


View more